Evidence map›Paper›PMID 42124418›Full record

ArticleZhongguo fei ai za zhi = Chinese journal of lung cancer2026

[Trastuzumab Deruxtecan for EGFR-mutant Lung Adenocarcinoma
with Acquired High-level HER2 Amplification: A Case Report].

Xiaoxiao Ge, Hefeng Chen, Shaohua Cui

Abstract readCase ReportsEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Article in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Xiaoxiao GeDepartment of Pulmonary and Critical Care Medicine, Huadong Hospital, Fudan University, Shanghai 200040, China.
Hefeng ChenDepartment of Pulmonary and Critical Care Medicine, Huadong Hospital, Fudan University, Shanghai 200040, China.
Shaohua CuiDepartment of Pulmonary and Critical Care Medicine, Huadong Hospital, Fudan University, Shanghai 200040, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Trastuzumab deruxtecan is a newly developed antibody-drug conjugate (ADC) designed to overcome human epidermal growth factor receptor 2 (HER2) aberrations. Studies have confirmed that Trastuzumab deruxtecan yields promising efficacy with a manageable safety profile in previously treated non-small cell lung cancer (NSCLC) patients harboring HER2 mutations. However, data on efficacy of Trastuzumab deruxtecan for acquired HER2-amplified NSCLC are limited. Here, we report a case of a patient with metastatic lung adenocarcinoma who developed acquired high-level HER2 amplification (20 copies) after 2nd-line Osimertinib. A partial response (PR) was achieved with reduced-dose Trastuzumab deruxtecan. Plasma next-generation sequencing (NGS) further confirmed successful inhibition of HER2 amplification. 
.

Indexed as

Adenocarcinoma of LungCamptothecinErb-b2 Receptor Tyrosine KinasesImmunoconjugatesLung NeoplasmsTrastuzumabErbB ReceptorsGene AmplificationHumansMaleMiddle AgedMutationCamptothecinEGFR protein, humanERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesErbB ReceptorsImmunoconjugatesTrastuzumabtrastuzumab deruxtecanAcquired resistanceCase reportHER2 amplificationLung neoplasmsTrastuzumab deruxtecan

Identifiers

PMID42124418
PMCPMC13167501

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.